CAR T-cell therapy for multiple myeloma and amyloidosis
Part of Blood & lymphatic, Cancer, Heart & circulation, Hormones & metabolism, Immune system & allergy clinical trials.
This study tests a new type of CAR T-cell therapy that targets a protein called GPRC5D on cancer cells. It's for people with multiple myeloma or AL amyloidosis that has returned or not responded to other treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older.
- You have multiple myeloma or AL amyloidosis that has returned or not responded to treatment.
- For multiple myeloma: you've had at least 3 prior treatments, including a proteasome inhibitor, an immunomodulatory drug, and an anti-CD38 antibody.
- For AL amyloidosis: you've had at least 2 prior treatments, including a proteasome inhibitor and an anti-CD38 antibody.
- You must be able to care for yourself (ECOG performance status 0-2) and have adequate organ function.
- You must agree to use effective birth control if you are of childbearing age.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new CAR-T cell treatment (HBI0101) for people with multiple myeloma or light-chain amyloidosis that has come back or stopped responding to other treatments. The therapy uses your own immune cells to fight cancer, and the goal is to see if it can help control the disease.
This trial tests a CAR T cell therapy that targets two proteins (CD19 and BCMA) on the surface of abnormal plasma cells. It is for people with AL amyloidosis whose disease has come back or did not respond to at least one prior treatment.
This trial tests a new CAR T cell therapy (arlocabtagene autoleucel) that targets a protein called GPRC5D on myeloma cells. It is for people whose multiple myeloma has come back or is not responding after trying at least four different types of treatment.
This Phase 1 trial tests a CAR T-cell treatment made to target a protein called GPRC5D on myeloma cells. It may help patients whose multiple myeloma or plasma cell leukemia has come back or stopped responding to prior treatments.
This study tests a new treatment using your own immune cells (called CAR-T cells) that are engineered to find and attack a specific protein (GPRC5D) on your myeloma cells. The goal is to see if it is safe and effective for people whose myeloma has not responded to other treatments.
This trial tests a new type of cell therapy (CAR-T cells) that targets a protein called GPRC5D on myeloma cells. It is for people with multiple myeloma that has come back or not responded to several prior treatments, including immunomodulators, proteasome inhibitors, and anti-CD38 antibodies.
Hear when a new Light Chain Amyloidosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.